




2nd International Meeting on Ischemia Reperfusion Injury in Transplantation

April 24-25,
2014

www.imirt.fr


Programme

Futuroscope,
Poitiers, France



Acknowledgements

The Organizing Committee wishes to extend its thanks and appreciation
to the following sponsors for their contribution :



and also





2nd International Meeting on Ischemia Reperfusion Injury in Transplantation

April, 24-25, 2014 - Futuroscope, Poitiers, France



Société
Francophone de
Transplantation




Scientific committee

Lionel Badet,
Benoît Barrou,
Michel Eugène,
René Ferrera,
Constantino Fondevila,
Peter Friend,
Thierry Hauet,
Henri Leuvenink,
Diethard Monbaliu,
Jacques Pirenne,
Rutger Ploeg,
Stefan G. Tullius,
Dirk Van Raemdonck

Organization committee

Lionel Badet,
Benoît Barrou,
Bertrand Doré,
Michel Eugène,
Thierry Hauet,
Christophe Jayle,
Gérard Mauco,
Michel Pinsard,
René Robert,
Guy Touchard



Scientific Programme

Thursday, April 24

9:00 Welcome address

1st session: New aspects of cell metabolism during IRI

Chairs: Nicolas Chatauret (Poitiers, France), Ina Jochmans (Leuven, Belgium)

01 - Keynote lecture: Autophagy in ischemia reperfusion injury

Invited speaker: Jean-Paul Decuyper (Leuven, Belgique)

02 - Microarray analysis after preoperative dietary restriction reveals potential mechanisms involved in the protection against renal ischemia-reperfusion injury

F. Jongbloed, T.C. Saat, M.E.T. Dollé, H. Van Steeg, J.H.J. Hoeijmakers, C.E. Payan Gomez, L.J.W. Van Der Laan, J.N.M. Ijzermans, R.W.F. De Bruin (Rotterdam, The Netherlands)

03 - Liraglutide protects cells from proinflammatory tissue factor bearing microparticles in an in vitro model of ischemia reperfusion: interest for pancreatic islets transplantation

C. Gleizes, A.A. Constantinescu, M. Abbas, B. Yver, F. Toti, L. Kessler (Strasbourg, France)

04 - Metabolomics analysis of urine and kidney samples after renal ischemia-reperfusion injury in mouse

F. Jouret, L. Poma, J-O. Defraigne, J.M. Krzesinski, P. De Tullio (Liège, Belgium)

05 - Inhibition of stress kinase-dependent pro-oxidant signaling prevents ischemia-reperfusion injury (IRI)

M. Ashraf, S. Khalid, M. Haller, M. Thurner, D. Dragun, J. Troppmair (Innsbruck, Austria)

06 - Functional contrast free magnetic resonance imaging (MRI) for early detection of ischemia induced acute kidney injury (AKI) and acute transplant rejection

F. Gueler, S. Rong, M. Peperhove, D. Hartung, S. Tewes, M. Meier, M. Gutberlet, F. Wacker, H. Haller, K. Hueper (Hannover, Germany)

O7 - Design of nanoparticle therapeutics for ischemia reperfusion injuries
Y. Nagasaki, T. Toru Yoshitomi, K. Kazuko Toh, A. Aiki Marushima,
H. Hideo Tsurushima, K. Kensuke Suzuki, A. Akira Matsumura,
A. Aki Hirayama, S. Shoji Sanada, A. Akemi (Tsukuba, Japan)

10:30 Break

11:00 2nd session: Immunology

Chair: André Herbelin (Poitiers, France)

Keynote lectures:

O8 - Complement and ischemia reperfusion injury

Invited speaker: Steven Sacks (London, UK)

O9 - IRI and chronic injury

Invited speaker: Olivier Thaunat (Lyon, France)

O10 - Protection against renal ischemia reperfusion injury by dietary restriction and fasting through downregulation of mannose-binding lectin

S. Shushimita, P. Van Der Pol, R.W.F. De Bruin, J. N. M. Ijzermans,
C. Van Kooten, F.J.M.F. Dor (Rotterdam, The Netherlands)

O11 - Recombinant C1INH reduces ischemia reperfusion-induced immune response and improves kidney graft outcome

R. Thuillier, S. Lepape, T. Saintyves, J. Danion, E. Van Amersfoort,
B. Oortwijn, G. Blancho, T. Hauet (Poitiers, France)

O12 - Endothelial progenitor cells improve the vascularization of the intramuscular site before islet implantation in the minipig

L. Quintane, T. Hubert, F. Pattou, N. Arrouche, G. Uzan, V. Gmyr, J. Kerr-Conte
(Villejuif, France)

12:30 Lunch

14:00 3rd session: IRI and cells

Chairs: Thierry Hauet (Poitiers, France),
Henri Leuvenink (Groningen, The Netherlands)

O13 - Keynote lecture: *Ischemia reperfusion, inflammatory signalling and dendritic cells*

Invited speaker: Fabrice Ivanes (Tours, France)

O15 - Determination of ischemia reperfusion mechanisms at the cellular level : the unfolded protein response

S. Lepape, T. Hauet, R. Thuillier (Poitiers, France)

O16 - Heat shock protein 90 inhibition with AT13387 abrogates TLR4-mediated NF-κB activity and protects from oxidative stress

S. O'Neill, E. Khoo, J. Hughes, J.A. Ross, S.J. Wigmore, E.M. Harrison (Edinburgh, UK)

O17 - Injury of peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures

S. Op Den Dries, A. Westerkamp, N. Karimian, A.S.H. Gouw, J. Markmann, T. Lisman, H. Yeh, K. Uygun, P. Martins, R.J. Porte (Groningen, The Netherlands)

O18 - HO-1-dependent CD11b+F4/80lo renal cells confer resistance against renal I/R

M. Rossi, S. Delbauve, A. Thierry, C. Spilleboudt, O. Leo, V. Flamand, A. Le Moine, J.M. Hougardy (Gosselies, Belgium)

O19 - Ischemia reperfusion injury induced acute kidney injury and later renal fibrosis are attenuated by complement deficiency

A. Thorenz, R. Chen, S. Rong, P. Dutow, M.S. Jang, H. Haller, A. Klos, F. Gueler (Hannover, Germany)

O20 - Role of inflammatory response in lung ischemia reperfusion injury in a model of organ-specific culture

H. Smail, J.M. Baste, A. Gay, J.P. Morin, P.Y. Litzler (Rouen, France)

15:30 Break

16:00 4th session: Donor management

Chairs: Michel Eugène (Poitiers, France), Chris Watson (UK)

O21 - Keynote lecture: Future in brain death donor management

Invited speaker: Dermot McKeon (UK)

O22 - Using proteomics and metabolomics as novel tools to identify mitochondrial dysfunction and metabolic dysregulation as critical factors in brain death induced kidney injury

M. Akhtar, H. Huang, M. Kaisar, H. Leuvenink, B. Kessler, S. Fuggle, C. Pugh, R. Ploeg (Oxford, UK)

O23 - Triphasic response of glomerular filtration rate after experimental brain death in pigs

W.G. van Rijt, N. Secher, A.K. Keller, U. Møldrup, Y. Chynau, R.J. Ploeg, H. Van Goor, R. Nørregaard, H. Birn, S. Rittig, H.G.D. Leuvenink, B. Jespersen (Groningen, The Netherlands)

O24 - A meta-analysis and meta-regression of outcomes including ischemic cholangiopathy in donation after cardiac death liver transplantation

S. O'Neill, A. Roebuck, E. Khoo, SJ. Wigmore, EM. Harrison (Edinburgh, UK)

O25 - α -melanocyte stimulating hormone treatment does not improve early graft function in porcine brain dead kidney transplantation

W.G. van Rijt, N. Secher, A.K. Keller, U. Møldrup, Y. Chynau, R.J. Ploeg, H. Van Goor, R. Nørregaard, H. Birn, J. Frøkiaer, S. Nielsen, H.G.D. Leuvenink, B. Jespersen (Groningen, The Netherlands)

O26 - Sudden onset of brain death leads to better rat kidney function than slow onset of brain death

D. Hoeksma, R.A. Rebollo, C.M.V. Hottenrott, M.E. Erasmus, H.G.D. Leuvenink (Groningen, The Netherlands)

O27 - Preclinical porcine model of ischemia-reperfusion injuries in the lung during cardiopulmonary bypass

J. Tomasi, S. Giraud, J. Danion, G. Allain, P. Corbi, T. Hauet, C. Jayle (Poitiers, France)

17:30 Poster session - Wine and cheese

> 19:00

Friday, April 25

7:30 Meet the experts sessions

> 8:15

8:30 **5th session: Organ conditioning (pre-per-post)**

Chairs: Frédéric Favreau (Poitiers, France), David Talbot (Newcastle upon Tyne, UK)

O28 - Keynote lecture: Update on (volatile) anesthetics in preventing ischemia-reperfusion injury

Invited speaker: Steffen Rex (Leuven, Belgium)

O29 - Remote ischemic preconditioning in neurological death organ donors (RIPNOD) decreases liver reperfusion injury-preliminary data

A. Bongu, J. Oliver, W.K. Washburn, A.K. Beidas, U. Pandit, M.K. Harris, G. Dikdan, J. Lewis, C. Tourtellot, C. Kadric, C. Welsh, J. Nespral, J. Radomski, A. Fisher, D. Wilson, B. Koneru (Newark, USA)

O30 - HEMO2Life®, a natural oxygen transporter, improves donor heart preservation during prolonged storage

E. Teh, V. Polard, F. Zal, P. Menasché, D. Chambers (London, UK)

O31 - Ischemic postconditioning of the liver graft in adult liver transplantation. Effects on ischemia-reperfusion injury and liver function

L. Ricca, A. Lemoine, M. Sebagh, E. Vibert, G. Balducci, D. Azoulay (Villejuif, France)

O32 - Ischaemic postconditioning reduces renal warm ischemia-reperfusion injury

S. Hosgood, J. Hunter, J. Barlow, M. Nicholson (Leicester, UK)

O33 - Preoperative fasting protects aged obese mice against renal ischemia-reperfusion injury

F. Jongbloed, R.W.F. De Bruin, S. Van Den Engel, L.J.W. Van Der Laan, H. Van Steeg, J.N.M. Ijzermans, M.E.T. Dollé (Rotterdam, The Netherlands)

O34 - Resuscitation of warm ischemia-damaged porcine kidney grafts by venous systemic oxygen persufflation using Ecosol

B. Doorschot, J. Kalenski, E. Mancina, P. Paschenda, C. Beckers, C. Bleilevens, P. Boor, R. Tolba (Aachen, Germany)

10:00 Break

10:30 6th session: Organ *ex vivo* repair

Chairs: Benoit Barrou (Paris, France), Sarah Hosgood (Leicester, UK)

O35 - Keynote lecture: Update on renal *ex vivo* warm perfusion

Invited speaker: Mikael Nicholson (Leicester, UK)

O36 - A novel method of protein delivery for *ex vivo* protection and repair of organs for transplantation

A. Venkatachalam, Q. Hu, C. Wood, S. Guler, I. Alwayn (Halifax, Canada)

O37 - An *ex vivo* perfusion system to achieve recovery of hearts sourced from marginal donors

O. Mownah, M. Khurram, C. Ray, R. Coates, F. Afzadi, S. Stamp, J. Brassil, D. Rees, J. Majo, S. Nair, S. Clark, G. McGowan, J. Dark, N. Carter, D. Talbot (Newcastle upon Tyne, UK)

O38 - Mimicking non-heart beating lung donors with hybrid model of *in vivo* ischemia followed by *in vitro* *ex vivo* lung perfusion (*in vitro* EVLP)

J.M. Baste, A. Gay, H. Smail, M. Bubenheim, H. Begueret, J.P. Morin, P.Y. Litzler (Rouen, France)

O39 - Microvesicles abrogate the effects of renal ischemia-reperfusion injury on kidney function

H. Whalen, M. Clancy, P. Shiels (Glasgow, UK)

O40 - Criteria for viability assessment of discarded human donor livers during *ex vivo* normothermic machine perfusion

M.E. Sutton, S. Op Den Dries, N. Karimian, M.T. De Boer, J. Wiersma-Buist, A.S.H. Gouw, H.G.D. Leuvenink, T. Lisman, R.J. Porte (Groningen, The Netherlands)

O41 - Anti-apoptotic effects of 3,3',5-triiodo-l-thyronine in the liver of brain-dead rats

R. Rebollo, A.C. Van Erp, J. Wiersma-Buist, H.G.D. Leuvenink, P. Romanque (Groningen, The Netherlands)

12:00 Lunch

13:00 7th session: Machine perfusion: why and how ?

Chairs: Lionel Badet (Lyon, France), Diethard Monbaliu (Leuven, Belgique)

O42 - Keynote lecture: *Machine perfusion of the liver; where are we going?*
Invited speaker: Robert Porte (Groningen, The Netherlands)

O43 - Metabolomic profile of perfusate and bile comparing machine perfusion with a new cell free oxygen carrier solution and cold storage preservation in a porcine model of liver transplantation

P. Fontes, W. Marsh, Y. Vodovotz, R. Lopez, A. Van Der Plaats, W. Light, G. Michalopoulos (Pittsburgh, USA)

O44 - Metabolomic analysis of perfusate from cadaveric kidneys stored by hypothermic machine perfusion

A. Guy, J. Nath, C. Ludwig, D. Tennant, N. Inston, M. Cobbold, A. Ready (Birmingham, UK)

O45 - Measurement of oxygen levels in human livers undergoing hypothermic oxygenated machine perfusion

H. Abudhaise, B. Fuller, B.R. Davidson (London, UK)

O46 - Machine perfusion following static cold storage in kidney transplantation decreases the duration of delayed graft function and time to hospital discharge

A. Pacheco-Silva, M. Borrelli Junior, L. Requia-Moura, M. Souza Durao Junior, M. Nogueira Junior, L. Pertusier, E. Tonato, AC. Carvalho De Matos (Sao Paulo, Brazil)

O47 - Are pre- and post-transplant renal hemodynamics measure with the perfusion machine and doppler ultrasound studies able to predict acute tubular necrosis?

D. Paredes, B. Pano, C. Bru, C. Nicolau, A. Ruiz, C. Rodriguez-Villar, L. Peri, R. Adalia, F. Oppenheimer (Barcelona, Spain)

O48 - Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers

S. Op Den Dries, N. Karimian, M. Sutton, M. Kuipers, J. Wiersma-Buist, P. Ottens, J. Kuipers, B.N. Giepmans, H.G.D. Leuvenink, T. Lisman, R.J. Porte (Groningen, The Netherlands)

14:30 8th session: Biomarkers

Chairs: Olivier Thaunat (Lyon, France), Raphael Thuillier (Poitiers, France)

O49 - Keynote lecture: Biomarkers in ischemia reperfusion injury

Invited speaker: Pierre Marquet (Limoges, France)

O50 - Neutrophil gelatinase associated lipocalin, but not kidney injury marker-1, correlates with duration of delayed graft function

E.K. van den Akker, D.A. Hesselink, O.C. Manintveld, J.N.M. IJzermans, R.W.F. de Bruin, F.J.M.F. Dor (Rotterdam, The Netherlands)

O51 - Role of lipocalin-2 in a murine kidney transplantation model of ischemia-reperfusion injury (IRI) and allograft rejection

M.I. Ashraf, H. Maier, S. Schneeberger, H. Schwelberger, K. Kotsch, H. Regele, F. Aigner (Innsbruck, Austria)

O52 - Hypothermic machine perfusion of the pancreas; a promising preservation method for islet isolation

M. Leemkuil, H.G.D. Leuvenink, M.A. Engelse, R.J. Ploeg, E.J.P. De Koning, C. Krikke (Groningen, The Netherlands)

15:30 Conclusions

16:00 End of the congress

Posters

P1 - The unfolded protein response (UPR) can participate to the liver ischemic post-conditioning protection against ischemia/reperfusion (I/R) injury via the modulation of NF-κB/CHOP/IL-1 β

L. Ricca, E. Lecorché, J. Hamelin, G. Baldacci, D. Azoulay, A. Lemoine (Villejuif, France)

P2 - Activation of the calcium-sensing receptor before renal ischemia/reperfusion exacerbates kidney injury in mouse

F. Jouret, P. de Tullio, L. Poma, R. Marée, C. Bovy, J.O. Defraigne, J.M. Krzesinski (Liège, Belgium)

P3 - N-octanoyl dopamine conditioning has an immediate effect on the mitochondrial electron transport chain

M. Hottenrott, J. Wedel, C. Mohansingh, J. Hillebrands, H. Leuvenink (Groningen, The Netherlands)

P4 - Solution SCOT15 improves early survival compared to the UW solution following rat liver transplantation in a strong allogenic combination

E. Savier, J. Danion, N. Chatauret, F. Favreau, S. Hosni, P. Levillain, T. Hauet (Paris, France)

P5 - Histological injury detected in biopsies of extrahepatic bile duct of donor livers represents injury in the rest of the biliary tree, including the intrahepatic bile ducts

N. Karimian, P. Weeder, F. Bomfati, S. Op Den Dries, J. Wiersma-Buist, A.S.H. Gouw, T. Lisman, R.J. Porte (Groningen, The Netherlands)

P6 - Cardioprotective effect of fondaparinux in a rat model of myocardial ischemia-reperfusion

S. Guillou, S. Tamareille, O. Blanchet, D. Prunier, P. Hibert, F. Prunier, L. Macchi (Angers, France)

P7 - Cinacalcet treatment at the time of transplantation is associated with a significant risk of delayed graft function in kidney transplant recipients

F. Jouret, L. Weekers, S. Grosch, C. Bonvoisin, M. Milicevic, O. Detry, J-M. Krzesinski (Liege, Belgium)

P8 - Increased inflammation and fibrosis caused by hyperoxaluria in an experimental model of renal ischemia reperfusion

A. Pacheco-Silva, R. Correia Da Silva, M. Correa-Costa, C. Favero Aguiar, M. Burgos Da Silva, M. Ioshie Hiyane, M. Antonio Cenedeze, N.O. Saraiva Câmara (Sao Paulo, Brazil)

P9 - Vasculotide administration in a brain death rat model

W.H. Westendorp, P.J. Ottens, H. Van Goor, R.J. Ploeg, H.G.D. Leuvenink (Groningen, The Netherlands)

P10 - The proper Ischemic preconditioning attenuates functional, metabolic, morphologic injury from renal ischemia-reperfusion injury in the mouse

J. Hwang, H. Choi, J. Kim, I. Moon (Seoul, Korea)

P11 - Gradual warming-up of kidneys reduces injury compared to immediate reperfusion

P. Mahboub, P. Ottens, R. Ploeg, H.G. Leuvenink (Groningen, The Netherlands)

P12 - N-octanoyl dopamine ameliorates lung function in the acute phase after lung transplantation

M. Hottenrott, C. Tsagogiorgas, A. Petersen, H. Leuvenink, M. Erasmus (Groningen, The Netherlands)

P13 - Early allograft dysfunction decreases patient survival after liver transplantation

N. Meurisse, S. Fieuws, I. Jochmans , W. Laleman, R. Aerts, F. Nevens, S. Van Der Merwe, C. Verslype, D. Cassiman, W. Van Steenbergen, J. Pirenne, D. Monbaliu (Leuven, Belgium)

P14 - Donor pre-treatment with the Geranylgeranylacetone derivate, NYK9354, reduces brain death-associated inflammation in the kidney at organ retrieval

L.F.A. van Dullemen, J.H. Kloeze, P.J. Ottens, S. Veldhuis, H. Steen, R.J. Ploeg, B.J.J.M. Brundel, H.G.D. Leuvenink (Groningen, The Netherlands ; Oxford, UK)

P15 - Flushing porcine DCD livers with Cyclo-Dextrin complexed curcumin does not reduce ischemia reperfusion injury

N. Meurisse, J. Parkinnen, L. Ceulemans, N. Gilbo, I. Jochmans, V. Heedfeld, T. Wylin, J. Pirenne, D. Monbaliu (Leuven, Belgium)

P16 - Viability assessment of discarded human kidneys using ex vivo normothermic perfusion

S. Hosgood, A. Barlow, M. Nicholson (Leicester, UK)

P17 - Initial experience of sequent « in situ / ex vivo » normothermic extracorporeal perfusion for resuscitation kidney from uncontrolled donors

A.E. Skvortsov, A.O. Reznik, A.P. Tutin, D.O. Kuzmin, A.A. Kutenkov, D.V. Gogolev, O.N. Reznik (St Petersburg, Russia)

P18 - New perfusion apparatus to improve cardiac graft viability during hypothermic transport

R. Ferrera, L. Augeul, J. Loufouat, D. Grinberg, E. Couture-Lepetit, N. Gallo-Bona, S. Lambert, M.C. Chablin, L. Sebbag, J.F. Obadia, M. Ovize (Lyon, France)

P19 - Machine perfusion preservation using ecosol attenuates warm ischemic damage in porcine kidney grafts

J. Kalenski, B. Doorschot, E. Mancina, P. Paschenda, C. Beckers, C. Bleilevens, P. Boor, R. Tolba (Aachen, Germany)

P20 - Influence of aging process on structure and function of rat livers subjected to ischemia/reperfusion

M. Trocha, A. Merwid-Lad, T. Sozanski, M. Piesniewska, P. Kowalski, A. Szela (Wroclaw, Poland)

P21 - Influence of aging process on selected parameters of oxidative stress in rat liver subjected to ischemia/reperfusion

M. Trocha, A. Merwid-Lad, T. Sozanski, M. Piesniewska, L. Ferencic-Golebiewska, A. Szela (Wroclaw, Poland)

P22 - Impact of ischaemia-reperfusion injury and steatosis in pre- and post-reperfusion biopsies on liver transplant outcomes

R. Sharma, A. Ciscar, E. Kontis, A. Athale, L. Souza, Y. Jabri, P. Srinivasan, A. Prachalias, N. Heaton, A. Quaglià, Y. Ma, W. Jassem (London, UK)

P23 - Novel rodent hybrid model of renal ischemia reperfusion injury / autotransplantation

H. Whalen, P. Shiels, M. Clancy (Glasgow, UK)

P24 - Natural history of kidney warm ischemic damage in rat model

A. Reznik, M. Skoblov, A. Skvortsov, D. Kuzmin, A. Tutin, D. Gogolev, A. Baranova, O. Reznik (St Petersburg, Russia)

P25 - A murine model of pulmonary ischemia and reperfusion injury: tricks of the trade

J. Gielis, G. Boulet, L. Maes, P. Van Schil (Wilrijk, Belgium)

Exhibitors' list

ASTELLAS PHARMA

Les Malesherbes - 114, rue Victor Hugo - 92300 Levallois-Perret - France

Phone: +33 (0)1 55 91 75 00 - Fax: +33 (0)1 55 91 75 68

www.astellas.com

BRIDGE TO LIFE EUROPE

www.bridgetolife.eu

1 Hardwick's Square - Hardwick's way, Wandsworth - London SW18 4AW - UK

Phone: +44 (0) 203-194-4291 - Fax: +44 (0) 203-004-1103

SANOFI FRANCE

www.sanofi.fr

9, boulevard Romain Rolland

75159 Paris cedex 14 - France

Phone: +33 (0)800 394 000

MACOPHARMA

www.macopharma.fr

200, chaussée Fernand Forest - 59200 Tourcoing - France

Phone: +33 (0)3 20 11 84 30 - Fax: +33 (0)3 20 11 84 86

ORGAN ASSIST

www.organ-assist.nl

L.J. Zielstraweg 1 - 9713 GX Groningen - The Netherlands

Phone: +31 (0)50 313 1905 - Fax: +31 (0)6 2365 7217

ORGAN RECOVERY SYSTEMS

www.organ-recovery.com

DaVincilaan 2 Box 6 - 1935 Zaventem - Belgium

Phone: +32 (0)2 715 00 00 - Fax: +32 (0)2 715 00 09

SANDOZ

www.sandoz.com

49, avenue Georges Pompidou - 92593 Levallois-Perret - France

Phone : +33 (0)1 49 64 58 55 - Fax : +33 (0)1 49 64 51 14

Prévention du rejet
du greffon chez les
transplantés hépatiques,
rénaux ou cardiaques

Traitement du rejet
de l'allograffe résistant
à un traitement par
d'autres médicaments
immunosuppresseurs

adoport™ TACROLIMUS

adoport **0,5 mg**, gélule

adoport **1 mg**, gélule

adoport **5 mg**, gélule



DÉNOMINATION DU MÉDICAMENT - FORME PHARMACEUTIQUE: ADOPORT 0,5 mg, gélule. Gélules de gélatine blanche opaque et ivoire contenant une poudre de couleur blanche à blanc cassé.

ADOPORT 1 mg, gélule. Gélules de gélatine blanche opaque et brun clair contenant une poudre de couleur blanche à blanc cassé. ADOPORT 5 mg, gélule. Gélules de gélatine blanche opaque et orange contenant une poudre de couleur blanche à blanc cassé. COMPOSITION QUALITATIVE ET QUANTITATIVE: Pour le 0,5 mg: Chaque gélule contient 0,5 mg de tacrolimus (sous forme de tacrolimus monohydraté). Excipient: Chaque gélule contient 48,5 mg de lactose monohydraté. Contenu de la gélule: Hypermellose (Methocel E6 LV), Lactose monohydraté, Croscarmellose sodique, Stéarate de magnésium. Enveloppe de la gélule: Gélatine, Dioxyde de titane (E171), Laurysulfate de sodium, Laurate de sorbitan, Oxide de fer jaune (E172). Pour le 1 mg: Chaque gélule contient 1 mg de tacrolimus (sous forme de tacrolimus monohydraté). Excipient: Chaque gélule contient 47,4 mg de lactose monohydraté. Contenu de la gélule: Hypermellose (Methocel E6 LV), Lactose monohydraté, Croscarmellose sodique, Stéarate de magnésium. Enveloppe de la gélule: Gélatine, Dioxyde de titane (E171), Laurysulfate de sodium, Laurate de sorbitan, Oxide de fer jaune (E172), Oxide de fer rouge (E172), Oxide de fer noir (E172). Pour le 5 mg: Chaque gélule contient 5 mg de tacrolimus (sous forme de tacrolimus monohydraté). Excipient: Chaque gélule contient 236,9 mg de lactose monohydraté. Contenu de la gélule: Hypermellose (Methocel E6 LV), Lactose monohydraté, Croscarmellose sodique, Stéarate de magnésium. Enveloppe de la gélule: Gélatine, Dioxyde de titane (E171), Laurysulfate de sodium, Laurate de sorbitan, Oxide de fer rouge (E172).

DONNÉES CLINIQUES: Indications thérapeutiques: Prévention du rejet du greffon chez les transplantés hépatiques, rénaux ou cardiaques. Traitement du rejet de l'allograffe résistant à un traitement par d'autres médicaments immunosuppresseurs. Posologie et mode d'administration:

Contre-indications: - Hypersensibilité au tacrolimus ou à d'autres macrolides. - Hypersensibilité à l'un des excipients. Mise en garde spéciales et Précautions d'emploi*: Interactions avec d'autres médicaments et autres formes d'interactions*, Grossesse et allaitement*, Effets sur l'aptitude à conduire des véhicules et à utiliser des machines*, Effets indésirables*, Surdosage*, PROPRIÉTÉS PHARMACOLOGIQUES : Propriétés pharmacodynamiques*: Classe pharmacothérapeutique: INHIBITEUR DE LA CALCINEURINE, Code ATC: L04AAD02. Propriétés pharmacocinétiques*: Données de sécurité préclinique*, DONNÉES PHARMACEUTIQUES: Durée de conservation*, Précautions particulières de conservation*, PRÉSENTATION ET NUMÉRO D'IDENTIFICATION ADMINISTRATIVE: Pour le 0,5 mg: AMM n° 34009 374 154 7 7: 50 gélules sous plaquette thermomorphée (PVC/PE/PVC/Aluminium) dans un suremballage en aluminium. Prix: 49,34 €. Pour le 1 mg: 34009 374 853 2 6: 50 gélules sous plaquette thermomorphée (PVC/PE/PVC/Aluminium) dans un suremballage en aluminium. Prix: 86,86 €. Pour le 5 mg: AMM n° 34009 374 856 1 6: 50 gélules sous plaquette thermomorphée (PVC/PE/PVC/Aluminium) dans un suremballage en aluminium. Prix: 390,59 €. Liste I - Prescription initiale hospitalière d'une durée de 6 mois. Sandoz - 49, avenue Georges Pompidou - 92593 Levallois-Perret Cedex - Tél.: 01 49 64 48 00. (MLGA 130423)

*Pour une information complète, consultez le texte intégral du RCP, soit sur le site Internet de l'ANSM, soit sur demande auprès du laboratoire.



Contact information

VBCE-IMIRT

43, rue de l'Abbé Grout
5015 Paris - France

Phone: +33 (0) 1 45 33 60 46

Fax: +33 (0) 1 45 33 57 15

E-mail: imirt@vbce.fr

www.imirt.fr

